HER-2 positivity rate in dogs with mammary carcinoma: a systematic review and meta-analysis
Λέξεις-κλειδιά:
HER-2 meta-analysis canine mammary tumor
Περίληψη
ΔΕΝ ΔΙΑΤΙΘΕΤΑΙ ΠΕΡΙΛΗΨΗ
Λεπτομέρειες άρθρου
- Πώς να δημιουργήσετε Αναφορές
-
UZABACI, E., OZYIGIT, M., ERCAN, I., & ARDA, O. (2020). HER-2 positivity rate in dogs with mammary carcinoma: a systematic review and meta-analysis. Περιοδικό της Ελληνικής Κτηνιατρικής Εταιρείας, 71(2), 2141–2148. https://doi.org/10.12681/jhvms.23639
- Τεύχος
- Τόμ. 71 Αρ. 2 (2020)
- Ενότητα
- Research Articles
Αυτή η εργασία είναι αδειοδοτημένη υπό το CC Αναφορά Δημιουργού – Μη Εμπορική Χρήση 4.0.
Οι συγγραφείς των άρθρων που δημοσιεύονται στο περιοδικό διατηρούν τα δικαιώματα πνευματικής ιδιοκτησίας επί των άρθρων τους, δίνοντας στο περιοδικό το δικαίωμα της πρώτης δημοσίευσης.
Άρθρα που δημοσιεύονται στο περιοδικό διατίθενται με άδεια Creative Commons 4.0 Non Commercial και σύμφωνα με την άδεια μπορούν να χρησιμοποιούνται ελεύθερα, με αναφορά στο/στη συγγραφέα και στην πρώτη δημοσίευση για μη κερδοσκοπικούς σκοπούς.
Οι συγγραφείς μπορούν να καταθέσουν το άρθρο σε ιδρυματικό ή άλλο αποθετήριο ή/και να το δημοσιεύσουν σε άλλη έκδοση, με υποχρεωτική την αναφορά πρώτης δημοσίευσης στο J Hellenic Vet Med Soc
Οι συγγραφείς ενθαρρύνονται να καταθέσουν σε αποθετήριο ή να δημοσιεύσουν την εργασία τους στο διαδίκτυο πριν ή κατά τη διαδικασία υποβολής και αξιολόγησής της.
Λήψεις
Τα δεδομένα λήψης δεν είναι ακόμη διαθέσιμα.
Αναφορές
Abadie J, Nguyen F, Loussouarn D, Peña L, Gama A, Rieder N, Belousov A, Bemelmans I, Jaillardon L, Ibisch C, Campone M (2018) Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. Breast cancerresearch and treatment 10: 208-214.
Almasri NM, Al Hamad M (2005) Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Research 7: R598-R604.
Araújo MR, Campos LC, Damasceno KA, Gamba CO, Ferreira E, Cassali GD (2016) HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival. Res Vet Sci 106:121-130.
Avci E (2018) Bayesian Meta-Analysis of Prevalence: Alzheimer’s Disease
in Europe. Turkiye Klinikleri J Biostat 10: 208-214.
Bertagnolli AC, Ferreira E, Dias EJ, Cassali GD (2011) Canine mammary mixed tumors: immunohistochemical expressions of EGFR and HER-2. Aust Vet J 89: 312-317.
Burrai GP, Tanca A, De Miglio MR, Abbondio M, Pisanu S, Polinas M, Pirino S, Mohammed SI, Uzzau S, Addis MF, Antuofermo E (2015) Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic, and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer? Tumour Biol 36: 9083-91.
Campos LC, Silva JO, Santos FS, Araújo MR, Lavalle GE, Ferreira E, Cassali GD (2015) Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer. J Vet Diagn Invest 27: 531-5.
Charpin C, Garcia S, Bouvier C, Martini F, Lavaut MN, Allasia C, Bonnier P, Andrac L (1997) c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients’ overall and disease-free survival. British Journal of Cancer 75: 1667-1673.
Damasceno KA, Ferreira E, Estrela-Lima A, Gamba CO, Miranda FF, Alves MR, Rocha RM, de Barros ALB, Cassali GD (2016) HER-2 and EGFR mRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland. PLoS One 11: e0160419.
Development Core Team R (2014) R: A language and environment for statistical computing. In: R version 3.4.0, https://www.R-project.org.
Dutra AP, Granja NVM, Schmitt FC, Cassali GD (2004) c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. Braz J Med Biol Res 37: 1673-1681.
Erdogan S, Kanık EA (2011) Determination of cut-off values for heterogeneity measurements according to Cochran Q heterogeneity test results in meta-analyses: A simulation study. Turkiye Klinikleri J Biostat 3:
-83.
Gama A, Alves A, Schmitt F (2008) Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 453: 123-32.
Gouvêa A, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H (2006) Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol 14: 103-108.
Hsu WL, Huang HM, Liao JW, Wong ML, Chang SC (2009) Increased survival in dogs with malignant tumors overexpressing HER-2 protein and detection of a silent single nucleotide polymırphism in the canine HER-2 gene. Vet J 180: 116-123.
Im KS, Kim IH, Kim NH, Lim HY, Kim JH, Sur JH ( 2013) Breed-related differences in altered BRCA1 expression, phenotype, and subtype in malignant canine mammary tumors. Vet J 195: 366-72.
Kim JH, Im KS, Kim NH, Yhee JY, Nho WG, Sur JH (2011) Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study. Vet J 189: 318-22.
Kurilj AG, Hohšteter M, Artuković B, Severin K, Šoštarić-Zuckermann IC, Beck A, Seiwerth, S, Sabočanec R, Grabarević Ž (2011) Histopathological evaluation and immunohistochemical study of estrogen receptor alpha, HER-2, and Ki-67 in canine neoplastic mammary lesions. Veterinarski Arhiv 81: 709-722.
Martín de las Mulas J, Ordás J, Millán Y, Fernández-Soria V, Ramón y Cajal S (2003) Oncogene HER-2 in canine mammary gland carcinomas. Breast cancer research and treatment 80, 363-367.
Millanta F, Caneschi V, Ressel L, Citi S, Poli A (2010) Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. J Comp Pathol 142: 36-42.
Muhammadnejad A, Keyhani E, Mortazavi P, Behjati F, Haghdoost IS (2012) Overexpression of her-2/neu in malignant mammary tumors; translation of clinicopathological features from dog to human. Asian Pac J Cancer Prev 13: 6415-21.
Nguyen F, Peña L, Ibisch C, Loussouarn D, Gama A, Rieder N, Belousov A, Campone M, Abadie J (2018) Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors. Breast Cancer Res Treat 167: 635-648.
Oh SY, Ryu HH, Yoo DY, Hwang IK, Kweon OK, Kim WH (2014) Evaluation
of FOXP3 expression in canine mammary gland tumors. Vet Comp Oncol 12: 20-28.
Peña L, Gama A, Goldschmidt MH, Abadie J, Benazzi C, Castagnaro M, Díez L, Gärtner F, Hellmén E, Kiupel M, Millán Y, Miller MA, Nguyen F, Poli A, Sarli G, Zappulli V, de las Mulas JM (2014) Canine Mammary Tumors: A Review and Consensus of Standard Guidelines on Epithelial and Myoepithelial Phenotype Markers, HER2, and Hormone Receptor Assessment Using Immunohistochemistry. Vet Pathol 51: 127-45.
Ressel L, Puleio R, Loria GR, Vannozzi I, Millanta F, Caracappa S, Poli A (2013) HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome. Res Vet Sci. 94: 299-305.
Ross JS, Fletcher JA (1998) The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. The Oncologist 3: 237-252.
Shin JI, Lim HY, Kim HW, Seung BJ, Sur JH (2015) Analysis of Hypoxia-Inducible Factor-1α Expression Relative to Other Key Factors in Malignant Canine Mammary Tumours. J Comp Pathol 153:101-10.
Silva ILD, Dias APM, Bertagnolli AC, Cassali GD, Ferreira E (2014) Analysis of EGFR and HER-2 expressions in ductal carcinomas in situ in canine mammary glands. Arq. Bras. Med Vet Zootec 66: 763-768.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neuproto-oncogene in human breast and ovarian cancer. Science 244:707-712.
Tas EO, Sag S, Ercan I (2018) Investigating the impact of polysomy 17 in breast cancer patients without amplification through meta-analysis. International Journal of Hematology and Oncology 28: 95-103.
